Mike Aperghis

855 total citations
5 papers, 156 citations indexed

About

Mike Aperghis is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Mike Aperghis has authored 5 papers receiving a total of 156 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 2 papers in Surgery. Recurrent topics in Mike Aperghis's work include Lung Cancer Diagnosis and Treatment (3 papers), Radiomics and Machine Learning in Medical Imaging (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Mike Aperghis is often cited by papers focused on Lung Cancer Diagnosis and Treatment (3 papers), Radiomics and Machine Learning in Medical Imaging (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Mike Aperghis collaborates with scholars based in Japan, United States and United Kingdom. Mike Aperghis's co-authors include Martin Reck, Tetsuya Mitsudomi, John V. Heymach, Helen Mann, Tamer M. Fouad, David H. Harpole, Stephanie Jones, Janis M. Taube, Gary J. Doherty and Gabriel Garbaos and has published in prestigious journals such as Cancer Research, Journal of Thoracic Oncology and Clinical Lung Cancer.

In The Last Decade

Mike Aperghis

5 papers receiving 155 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mike Aperghis Japan 5 133 117 23 11 8 5 156
Fumihiro Tanaka Japan 7 132 1.0× 98 0.8× 16 0.7× 16 1.5× 5 0.6× 12 146
J. Casal Rubio Spain 4 103 0.8× 110 0.9× 11 0.5× 5 0.5× 7 0.9× 13 121
Nivedita Aanur United States 5 108 0.8× 149 1.3× 24 1.0× 3 0.3× 5 0.6× 6 164
Aurelia Alexandru Romania 8 111 0.8× 111 0.9× 10 0.4× 7 0.6× 14 1.8× 24 155
Elodie Amour France 6 136 1.0× 77 0.7× 12 0.5× 13 1.2× 6 0.8× 14 160
Sherif Raouf United Kingdom 8 46 0.3× 82 0.7× 21 0.9× 5 0.5× 13 1.6× 13 111
E. Felip Font Spain 6 77 0.6× 89 0.8× 8 0.3× 7 0.6× 9 1.1× 15 109
Dae Ho Lee South Korea 4 110 0.8× 171 1.5× 16 0.7× 4 0.4× 10 1.3× 6 182
Kathi Seidl-Rathkopf United States 3 48 0.4× 88 0.8× 9 0.4× 4 0.4× 9 1.1× 6 112
A. Li United States 6 101 0.8× 142 1.2× 12 0.5× 3 0.3× 3 0.4× 13 149

Countries citing papers authored by Mike Aperghis

Since Specialization
Citations

This map shows the geographic impact of Mike Aperghis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mike Aperghis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mike Aperghis more than expected).

Fields of papers citing papers by Mike Aperghis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mike Aperghis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mike Aperghis. The network helps show where Mike Aperghis may publish in the future.

Co-authorship network of co-authors of Mike Aperghis

This figure shows the co-authorship network connecting the top 25 collaborators of Mike Aperghis. A scholar is included among the top collaborators of Mike Aperghis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mike Aperghis. Mike Aperghis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

5 of 5 papers shown
1.
Heymach, John V., David Harpole, Janis M. Taube, et al.. (2024). OA13.03 Perioperative Durvalumab for Resectable NSCLC (R-NSCLC): Updated Outcomes from the Phase 3 AEGEAN Trial. Journal of Thoracic Oncology. 19(10). S38–S39. 5 indexed citations
2.
Heymach, John V., David H. Harpole, Tetsuya Mitsudomi, et al.. (2023). Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. Cancer Research. 83(8_Supplement). CT005–CT005. 55 indexed citations
3.
He, Jianxing, Shugeng Gao, Martin Reck, et al.. (2023). OA12.06 Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable EGFR-mutated NSCLC (AEGEAN). Journal of Thoracic Oncology. 18(11). S72–S73. 7 indexed citations
4.
5.
Heymach, John V., Janis M. Taube, Tetsuya Mitsudomi, et al.. (2019). P1.18-02 The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC. Journal of Thoracic Oncology. 14(10). S625–S626. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fumihiro Tanaka Breakdown of academic impact, for papers by J. Casal Rubio Breakdown of academic impact, for papers by Nivedita Aanur Breakdown of academic impact, for papers by Aurelia Alexandru Breakdown of academic impact, for papers by Elodie Amour Breakdown of academic impact, for papers by Sherif Raouf Breakdown of academic impact, for papers by E. Felip Font Breakdown of academic impact, for papers by Dae Ho Lee Breakdown of academic impact, for papers by Kathi Seidl-Rathkopf Breakdown of academic impact, for papers by A. Li
Rankless by CCL
2026